Sachit Saksena

Jun 10, 2024 | biorxiv.org | Peter Winter |Michelle L. Ramseier |Andrew W. Navia |Sachit Saksena

AbstractEfforts to cure BCR::ABL1 B cell acute lymphoblastic leukemia (Ph+ ALL) solely through inhibition of ABL1 kinase activity have thus far been insufficient despite the availability of tyrosine kinase inhibitors (TKIs) with broad activity against resistance mutants. The mechanisms that drive persistence within minimal residual disease (MRD) remain poorly understood and therefore untargeted.